Results from the largest community-based clinical trial to date, involving more than 3000 patients, has shown that adding the cholesterol absorption inhibitor ezetimibe to ongoing stable statin ...

A Swedish database of over 35,000 individuals found better cardiovascular outcomes when ezetimibe was added earlier to statin therapy for secondary prevention. Study authors deemed ezetimibe a ...

Compared with standard high-dose statin therapy, combination therapy with a moderate-intensity statin plus ezetimibe seems to reduce the risk of cardiovascular events to a similar degree over 3 years ...

Please provide your email address to receive an email when new articles are posted on . Ezetimibe conferred no increased risk for new-onset diabetes among IMPROVE-IT participants. The findings were ...

A recent simulation study published in the journal Scientific Reports analyzed representative data of over two million outpatients in Germany, in which the researchers reported that a combination of ...

Please provide your email address to receive an email when new articles are posted on . Obicetrapib plus ezetimibe lowered LDL nearly 50% vs. placebo in patients with high atherosclerotic risk.

Announcing a new article publication for Cardiovascular Innovations and Applications journal. According to the findings of randomized controlled trials, blood lipid levels in patients with coronary ...

Obicetrapib, a Lazarus-like cholesteryl ester transfer protein (CETP) inhibitor currently on its second life, checked another box in its development program with investigators showing the drug could ...

Navar A. Efficacy and safety of enlicitide, an oral PCSK9 inhibitor, for lowering LDL cholesterol in adults with or at-risk for ASCVD: the phase 3 CORALreef lipids trial. Presented at: AHA 2025 ...

Adding ezetimibe (Zetia) therapy to statins early after a heart attack improved outcomes, Swedish national records suggested. With statins almost universally used in this setting, people who also got ...